Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the sale, the insider owned 8,752 shares of the company’s stock, valued at $216,086.88. The trade was a 38.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Hims & Hers Health Price Performance
Shares of HIMS stock traded down $1.75 during trading hours on Wednesday, reaching $23.23. The company’s stock had a trading volume of 34,826,246 shares, compared to its average volume of 35,648,238. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The firm’s 50 day simple moving average is $23.43 and its 200-day simple moving average is $37.08. The company has a quick ratio of 1.70, a current ratio of 1.90 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $5.30 billion, a price-to-earnings ratio of 45.55, a PEG ratio of 2.42 and a beta of 2.55.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its quarterly earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. During the same quarter in the previous year, the firm earned $0.11 EPS. Hims & Hers Health’s revenue was up 28.4% on a year-over-year basis. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.
Institutional Inflows and Outflows
Key Stories Impacting Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Partnership with Novo Nordisk gives HIMS direct telehealth access to Ozempic and Wegovy, expanding its addressable market for weight‑loss/diabetes prescriptions and enabling a pre‑launch waitlist that could drive near‑term patient acquisition. Hims & Hers opens up pre-launch waitlist for Ozempic and Wegovy
- Positive Sentiment: The deal also resolves public friction between the companies and broadens branded GLP‑1 distribution via telehealth — a strategic win that supports HIMS’s growth narrative if conversion and pricing hold. Novo Nordisk Telehealth Deal With Hims And Hers Puts GLP-1 Pricing In Focus
- Neutral Sentiment: Sell‑side and value commentators are highlighting HIMS as a potential long‑term beneficiary of GLP‑1 demand; these bullish previews could help sentiment but depend on execution and margin outcomes. Leerink Partners Forecasts Strong Price Appreciation for Hims & Hers Health Value Investing With Raul Shah
- Negative Sentiment: Major insider selling: COO Michael Chi sold 97,289 shares (~$2.4M) and other insiders (Soleil Boughton, Irene Becklund) also trimmed positions on Mar 17 — large insider sales can be read as a negative signal by investors even if not uncommon. SEC filings: Michael Chi Form 4 Soleil Boughton Form 4 Irene Becklund Form 4
- Negative Sentiment: GLP‑1 pricing competition is heating up (HSBC and other analysts): faster price cuts or competitive pressure from Lilly and copycat drugs could compress margins and reduce the revenue upside of greater volume. Health Care Roundup: Market Talk
Analyst Upgrades and Downgrades
HIMS has been the subject of a number of research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. Truist Financial reiterated a “hold” rating and set a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Evercore set a $24.00 price target on shares of Hims & Hers Health in a report on Tuesday, February 24th. Finally, Bank of America upgraded Hims & Hers Health from an “underperform” rating to a “neutral” rating and increased their price target for the company from $12.50 to $23.00 in a research note on Tuesday, March 10th. Three equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $31.29.
Hims & Hers Health Company Profile
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
See Also
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
